Amgen Inc.

Makoto Kakutani

Jay Patrick Powers

Hiroyuki Goto

Shinji Yata

Yasuhiro Ohe

Pingchen Fan

Daqing Sun

Xuelei Yan

Dustin L McMinn

Yosup Rew

Marc Labelle

Mario G Cardozo

Xiao He

Katsuaki Imamura

Isamu Matsuda

Kazuhito Harada

Hua Tu

Jun Nishiu

Dustin L Mcminn

The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound has superior HSD1 inhibitory activity, and is useful as an HSD1 inhibitor, a therapeutic drug of diabetes or a therapeutic drug of obesity or a therapeutic drug of metabolic syndrome.

Triazole compounds and uses related thereto

Aryl sulfone compounds of formula I and II are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: 

Arylsulfones and uses related thereto

The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound is useful as a therapeutic drug for the treatment of diabetes, obesity or metabolic syndrome. 

Substituted pyrazoles are provided that are useful for the treatment of, for example, diabetes, obesity and metabolic syndrome.

Pyrazole compounds and uses related thereto

Growing community of inventors

Takatsuki, Japan

Makoto Kakutani